BR112019001217A2 - peptídeos cíclicos como antagonistas de receptor de c5a - Google Patents

peptídeos cíclicos como antagonistas de receptor de c5a

Info

Publication number
BR112019001217A2
BR112019001217A2 BR112019001217-6A BR112019001217A BR112019001217A2 BR 112019001217 A2 BR112019001217 A2 BR 112019001217A2 BR 112019001217 A BR112019001217 A BR 112019001217A BR 112019001217 A2 BR112019001217 A2 BR 112019001217A2
Authority
BR
Brazil
Prior art keywords
receptor antagonists
cyclic peptides
disorders
processes
formula
Prior art date
Application number
BR112019001217-6A
Other languages
English (en)
Inventor
Che Ye
Feng Yiqing
Merrill Hayward Matthew
Hepworth David
Jones Peter
Kaila Neelu
Papaioannou Nikolaos
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BR112019001217A2 publication Critical patent/BR112019001217A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"peptídeos cíclicos como antagonistas de receptor de c5a". a presente invenção refere-se aos derivados de peptídeo cíclico, ao seu uso na medicina, às composições contendo-os, aos processos para sua preparação e aos intermediários usados em tais processos. mais particularmente, a invenção refere-se aos antagonistas de receptor de c5a de peptídeo cíclico de fórmula (ia) ou fórmula (ib), ou sais farmaceuticamente aceitáveis dos mesmos, em que r1a, r1b, r2, r3 e r4 são como definidos na descrição. antagonistas de receptor de c5a são potencialmente úteis no tratamento de uma ampla variedade de distúrbios, incluindo distúrbios inflamatórios e distúrbios imunológicos.
BR112019001217-6A 2016-07-29 2017-07-17 peptídeos cíclicos como antagonistas de receptor de c5a BR112019001217A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662368262P 2016-07-29 2016-07-29
US62/368,262 2016-07-29
US201762517215P 2017-06-09 2017-06-09
US62/517,215 2017-06-09
PCT/IB2017/054314 WO2018020358A1 (en) 2016-07-29 2017-07-17 Cyclic peptides as c5 a receptor antagonists

Publications (1)

Publication Number Publication Date
BR112019001217A2 true BR112019001217A2 (pt) 2019-04-30

Family

ID=59416754

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001217-6A BR112019001217A2 (pt) 2016-07-29 2017-07-17 peptídeos cíclicos como antagonistas de receptor de c5a

Country Status (13)

Country Link
US (1) US20190270778A1 (pt)
EP (1) EP3491005A1 (pt)
JP (1) JP2019532021A (pt)
KR (1) KR20190032534A (pt)
CN (1) CN109563136A (pt)
AU (1) AU2017304103A1 (pt)
BR (1) BR112019001217A2 (pt)
CA (1) CA3031895A1 (pt)
IL (1) IL264537A (pt)
MA (1) MA45770A (pt)
MX (1) MX2019001153A (pt)
SG (1) SG11201811412XA (pt)
WO (1) WO2018020358A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
EP1498422A1 (de) * 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
CN1997384A (zh) * 2004-03-26 2007-07-11 普罗米克斯有限公司 使用补体C5a受体调节剂治疗神经系统病症
JP2008526915A (ja) 2005-01-17 2008-07-24 イエリニ・アクチェンゲゼルシャフト Ｃ５ａ受容体アンタゴニスト

Also Published As

Publication number Publication date
CN109563136A (zh) 2019-04-02
MA45770A (fr) 2019-06-05
CA3031895A1 (en) 2018-02-01
EP3491005A1 (en) 2019-06-05
JP2019532021A (ja) 2019-11-07
IL264537A (en) 2019-02-28
SG11201811412XA (en) 2019-02-27
WO2018020358A1 (en) 2018-02-01
MX2019001153A (es) 2019-06-10
US20190270778A1 (en) 2019-09-05
AU2017304103A1 (en) 2019-01-17
KR20190032534A (ko) 2019-03-27

Similar Documents

Publication Publication Date Title
ECSP21004787A (es) Inhibidores de inflamasoma nlrp3
BR112014030173A2 (pt) derivados de benzimidazol-prolina
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
BR112015007516A2 (pt) antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
BR112014010617A8 (pt) Derivados de 2-(1,2,3-triazol-2-il)benzamida e 3-(1,2,3-triazol-2-il)picolinamida como antagonistas do receptor de orexina
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
BR112014009102A2 (pt) compostos químicos
BR112016003348A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
BR112017019779A2 (pt) composto, e, composição farmacêutica
BR112017022008A2 (pt) composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios
UY35275A (es) Derivados de aminopirazina
EA201690888A1 (ru) Новые гетероциклические соединения
BR112016008799A8 (pt) derivados de pirazolopirimidona ou pirrolotriazona, seus usos, seus processos para sua preparação e seus intermediários, e composição farmacêutica
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
BR112017008794A2 (pt) inibidores de di-heteroaril histona desacetilase e seu uso em terapia
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201501163A1 (ru) Модуляторы рецептора cxcr7
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2628 DE 18-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.